As an example, tumor-derived prostaglandin E2 (PGE2) and transforming growth factor- β (TGF- β) synergistically suppress the production of IFN-I and tumor necrosis factor (TNF) in activated pDCs, which then exhibit a tolerogenic phenotype [45]. This evidence concerns the gene TNF and neoplasm.